Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB308
- Development stage
- Preclinical
- Lead developer
- SanBio
- Modality
- Cell Therapies
01
Overview
SB308 is a regenerative cell therapy developed by SanBio Co Ltd. It is designed to treat muscle dystrophy, aiming for muscle regeneration. As a cell therapy, it likely functions by promoting the body's natural regenerative processes, similar to other SanBio pipeline products which involve allogeneic transplantation of modified mesenchymal stem cells to secrete growth factors and attract endogenous stem cells to damaged tissue.
Beyond the preview
Go deeper on SB308.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB308.